CClinicalTrials.gg
CompletedNCT02622126Updated Nov 8, 2016

Colloid Pre-Loading on D-Dimer During Cesarean Section Under Spinal Anesthesia

A Phase 2 interventional study of hydroxyethyl starch (6% 130/0.4) and Hyperbaric bupivacaine in Coagulation Defect; Bleeding, sponsored by Assiut University. Completed at 1 site in Egypt. Open to female participants aged 19 Years to 50 Years. Per ClinicalTrials.gov, last updated 2016-11-08.

Sponsored by Assiut University · Phase 2, Interventional, and Prevention

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
19 Years to 50 Years
Sex
Female
01

Study summary

Maternal hypotension is the most frequent complication of a spinal Anesthesia. The prevention of spinal hypotension appears more likely to decrease the frequency and severity of associated adverse maternal symptoms than the treatment of established hypotension. Intravenous fluid administration prior to spinal anesthesia for caesarean section is accepted standard practice. The choice of fluid depends on individual and institutional habit, material cost (crystalloid is considerably cheaper) and the perceived relative benefits and risks. Uncommon but potentially serious adverse effect of colloids is impaired coagulation. Although pregnancy is associated with hypercoagulability, little is known about the effects of colloid preloading on coagulation in pregnant patients.

Read the detailed description

The patients were divided into two equal group of thirty patients in each group; Control group (normotensive pregnant women) and Mild preeclampsia group. In both groups patients preloaded with 500 mL hydroxyethyl starch (HES) 6% (130/0.4) (Voluven). Spinal anesthesia will be performed with intrathecal 10-12 mg hyperbaric bupivacaine in addition to 200 meg morphine. The patient was placed supine with left lateral tilt to alleviate aortocaval compression. 10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used co loading during the duration of the operation. Blood pressure was measured and recorded every three minutes. If severe hypotension (fall of > 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used. The blood pressure will rechecked 1 minute after each doses of ephedrine. If hypotension persisted after 30 mg of ephedrine, an additional 2 ml/kg of isotonic 0.9 NaCl solutions will be infused rapidly. Maternal hypotension is defined as at least a single administration of ephedrine within the period from induction of spinal anesthesia until transfer to postoperative recovery unit. Reactive hypertension is characterized as a blood pressure 20% greater than baseline mean levels after the use of the vasopressor. Bradycardia is defined as a fall of >30% of heart rate from baseline or \<50 beats /minute. Bradycardia, and when associated with hypotension it will be treated with 0.5 mg of atropine intravenous. Upon completion of the cesarean section, the subject will be transported to the postanesthesia care unit (PACU).

02

Conditions studied

  • Coagulation Defect; Bleeding

Keywords

  • Preloading
  • Colloid
  • Cesarean section
  • D-dimer
  • Hypotension
03

In context

Hemostatic Disorders

503 studies on the registry are indexed under Hemostatic Disorders; 71 are open to participants now.

This study's enrollment of 60 is above the median of 51 across 253 interventional studies indexed under Hemostatic Disorders.

Browse Hemostatic Disorders studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • American Society of Anesthesiologist (ASA) status I or II
  • Aged >18 years
  • Singleton pregnancy
  • Gestational age ≥ 37 weeks
  • Height ≥ 150 cm and ≤ 180 cm
  • Weight > 50 kg and \< 100 kg
  • Eligible for spinal anesthesia
  • Elective cesarean delivery

Exclusion criteria

Exclusion Criteria:

  • Multiple pregnancies
  • Cardiovascular disease cerebrovascular disease
  • Diabetes Mellitus
  • Hematological problems
  • Abnormal coagulation tests
  • Anticoagulant use
  • Hemorrhagic syndromes of pregnancy (placenta previa or accidental hemorrhage)
  • Regular NSAIDS treatment
  • HELLP syndrome
  • Severe preeclampsia
  • Eclampsia
  • Termination of pregnancy for any cause
  • Peripheral neuropathy or chronic pain syndrome
  • Local infection or injury at the needle entry point
  • Known hypersensitivity reaction to local anesthetic, starch allergy
  • Height \< 150 cm and > 180 cm
  • Weight \< 50 kg and > 100 kg
  • Patient refusing spinal anesthesia
  • Fetal anomalies
  • Fetal distress or cases with umbilical cord prolapsed
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Normotensive pregnant women group

    Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven). Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of \> 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension)

    Drug: hydroxyethyl starch (6% 130/0.4) · Drug: Hyperbaric bupivacaine · Drug: Morphine · Drug: Isotonic 0.9 sodium chloride (NaCl) solution · Drug: Ephedrine · Drug: Atropine

  • Active comparator
    Mild preeclampsia pregnant women group

    Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven). Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of \> 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension)

    Drug: hydroxyethyl starch (6% 130/0.4) · Drug: Hyperbaric bupivacaine · Drug: Morphine · Drug: Isotonic 0.9 sodium chloride (NaCl) solution · Drug: Ephedrine · Drug: Atropine

Interventions

  • Drughydroxyethyl starch (6% 130/0.4)

    preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).

    Also known as: Voluven

  • DrugHyperbaric bupivacaine

    Sub arachnoid 10-12 mg hyperbaric bupivacaine

    Also known as: Marcaine

  • DrugMorphine

    Sub arachnoid 200 meg morphine

  • DrugIsotonic 0.9 sodium chloride (NaCl) solution

    10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation

    Also known as: Normal saline

  • DrugEphedrine

    If severe hypotension (fall of \> 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.

  • DrugAtropine

    Bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.

06

What researchers measure

Primary outcomes

  1. Coagulation defect (detection of D-Dimer) of the mother

    Blood samples for detection of D-Dimer were taken from the mother preoperatively (before colloid administration) and another one at the end of the operation

    Time frame: Pre and post cesarean delivery, an expected average of 90 minutes

  2. Coagulation defect (detection of D-Dimer) of the baby

    Blood sample for detection of D-Dimer was taken from the umbilical cord of the fetus before clamping

    Time frame: Pre and post cesarean delivery, an expected average of 90 minutes

Secondary outcomes

  1. Maternal hypotension (fall of > 20% of MAP (mm Hg ) from baseline)

    fall of \> 20% of MAP (mm Hg ) from baseline

    Time frame: Post spinal for cesarean delivery, an expected average of 4 hours

  2. Ephedrine treatment (Ephedrine total dosage (mg))

    Ephedrine total dosage (mg)

    Time frame: Post spinal for cesarean delivery, an expected average of 4 hours

  3. Atropine treatment (atropine total dosage (mg))

    atropine total dosage (mg)

    Time frame: Post spinal for cesarean delivery, an expected average of 4 hours

  4. Hemoglobin concentration

    Blood samples for detection of hemoglobin concentration gm/dL

    Time frame: Pre and post cesarean delivery, an expected average of 4 hours

  5. Platelet count

    Blood samples for detection of platelet count (109/L )

    Time frame: Pre and post cesarean delivery, an expected average of 4 hours

07

Study locations

1 site
  • Faculty of Medicine
    Assiut, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02622126
Lead sponsor
Assiut University
Responsible party
Sayed Kaoud Abd-Elshafy (Associate Professor (Anesthesiology and Critical Care)- College of Medicine-Assiut University, Assiut University) — Principal investigator
First posted
Dec 4, 2015
Start date
Jan 2016
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Nov 8, 2016

Study contacts

sayed abd elshafy, MD
principal investigator · associate professor

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion